Treatment options for multidrug-resistant bacteria

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 4, 2006, Pages 601-618

  Giamarellou, Helen ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Acinetobacter baumannii; Enterobacteriaceae; ESBL+; Immunointervention; MRSA; Multidrug resistant bacteria; Pseudomonas aeruginosa; Therapy; Vancomycin resistant Enterococcus

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTOBIPROLE; CETHROMYCIN; CILASTATIN; CIPROFLOXACIN; CLINDAMYCIN; COLISTIMETHATE; COLISTIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DORIPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FROPENEM; GARENOXACIN; GENTAMICIN; IMIPENEM; LINEZOLID; ORITAVANCIN; PROMIXIN; RAMOPLANIN; RIFAMPICIN; SULBACTAM; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANEMIA; ANOREXIA; ANTIBIOTIC RESISTANCE; APNEA; ARTHRALGIA; ATAXIA; BACTERIAL INFECTION; BACTERIUM ISOLATE; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFUSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MISUSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DYSPEPSIA; ENTEROBACTERIACEAE; FACE DISORDER; HEALTH CARE POLICY; HOSPITAL INFECTION; HUMAN; IMMUNOSTIMULATION; INFECTION CONTROL; INTENSIVE CARE UNIT; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OPTIC NEURITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PRESCRIPTION; PRURITUS; PSEUDOMONAS AERUGINOSA; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; REVIEW; SKIN APPENDAGE DISEASE; SKIN MANIFESTATION; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; URTICARIA; VANCOMYCIN RESISTANT ENTEROCOCCUS; VERTIGO; VISUAL DISORDER; VOMITING; WEAKNESS;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 33749537281     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.4.601     Document Type: Review

References (133)

1. Cohen ML. Epidemiology of drug resistance: implications for a post-antibiotic era. Science 257(5073), 1050-1055 (1992).
2. Diekema DJ, Boots Miller BJ, Vaughn TE et al. Antimicrobial resistance trends and outbreak frequency. Clin. Infect. Dis. 38(1), 1278-1288 (2004).
3. Canton R, Coque TM, Baquero F. Multiresistant Gram-negative bacilli: from epidemics to endemics. Curr. Opin. Infect. Dis. 16(4), 1278-1275 (2003).
4. Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5(2), 115-119 (2005).
5. Alexandria VA. Bad bugs, no drugs: as antibiotic R&D stagnates, a public health crisis brews. Infectious Diseases Society of America (2004).
6. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6(5), 427-430 (2003).
7. Powers JH. Development of drugs for antimicrobial-resistant pathogens. Curr. Opin. Infect. Dis. 16(6), 547-551 (2003).
8. Talbot GH, Bradley J, Edwards JE et al. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42(5), 657-668 (2006).
9. Wenzel RP. The antibiotic pipeline-challenges, costs, and values. N. Engl. J. Med. 351(6), 523-526 (2004).
10. Powers JH. Antimicrobial drug development - the past, the present, and the future. Clin. Microbiol. Infect. 10(Suppl. 4), 23-31 (2004).
11. Maltezou HC, Giamarellou H. Community-acquired methicillin-resistant Staphylococcus aureus infections. Int. J. Antimicrob. Agents 27(2), 87-96 (2006).
12. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic and therapeutic Odyssey. Clin. Infect. Dis. 40(4), 562-573 (2005).
13. Walsh TR, Bolmström A, Qwärnstrm A et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39(7), 2439-2444 (2001).
14. Goldstein FW, Kitzis MD. Vancomycin-resistant Staphylococcus aureus: no apocalypse now. Clin. Microbiol. Infect, 9(8), 761-765 (2003).
15. Mascini EM, Bonten MJM. Vancomycin-resistant enterococci: consequences for therapy and infection control. Clin. Microbiol. Infect. 11(S4), 43-56 (2005).
16. Diaz Granados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections; a meta-analysis. Clin. Infect. Dis. 41(3), 327-333 (2005).
17. Giamarellou H. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum β-lactamases (ESBLs). Clin. Microbiol. Infect. 11(Suppl. 4), 1-16 (2005).
18. Turner PJ. Extendcd-spectrum β-lactamases. Clin. Infect. Dis. 41(Suppl. 4), 273-275 (2005).
19. Hanberger H, Diekema DJ, Fluit A et al. Surveillance of antibiotic resistance in European ICUs. I. Hosp. Infect. 48(1), 161-176 (2001).
20. M'Zali FH, Chanawong A, Kerr RB, Birkenhead D, Hawkey PM. Detection of extended-spectrum β-lactamases in members of the family enterobactericeae: comparison of the MAST DD test, the double disc and the Etest. J. Antimicrob. Chemother. 45(6), 881-885 (2000).
21. Paterson DL, Ko WC, Gottberg AV et al, Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended spectrum β-lactamases. Clin. Infect. Dis. 39(1), 31-37 (2004).
22. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin. Microbiol. Infect. 11(S4), 17-32 (2005).
23. Fritsche TR, Sader HS, Toleman MA, Walsh TR, Jones RN. Emerging metallo β-lactamase-mediated resistances: a summary report from the worldvide SENTRY antimicrobial surveillance program. Clin. Infect. Dis. 41(Suppl. 4), 276-278 (2005).
24. Walsh TR, Toleman MA, Poirel L, Nordman P. Metallo-β-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18(2), 306-325 (2005).
25. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob. Agents Chemother. 49(4), 1306-1311 (2005).
26. Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin. Infect. Dis. 37(2), 214-220 (2003).
27. Landman D, Quale JM, Mayorga D et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch. Intern. Med. 162(13), 1515-1520 (2002).
28. Brown S, Amyes S. OXA β-lactamases in Acinetobacter: the story so far. J. Antimicrob. Chemother. 57(1), 1-3 (2006).
29. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu. Rev. Biochem. 46, 723-763 (1977).
30. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multi-drug resistant Gram-negative bacterial infections. Clin. Infect. Dis. 40(9), 1333-1341 (2005).
31. Koyama Y, Kurosasa A, Tsuchiya A, Takakuta K. A new antibiotic colistin produced by spore-forming soil bacteria. J. Antibiot. (Tokyo) 3, 457-458 (1950).
32. Schindler M, Osborn MJ. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 18(20), 4425-4430 (1979).
33. Koike M, Iika K, Matsuo T. Electron microscopic studies on mode of action of polymyxin. J. Bacteriol. 97(1), 448-452 (1969).
34. Moore RA, Chan L, Hancock RE. Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 26(4), 539-545 (1984).
35. Bengoechea JA, Skurnik M. Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia. Mol. Microbiol. 37(1), 67-80 (2000).
36. Ito-Kagawa M, Koyama Y. Selective cleavage of a peptide antibiotic, colistin by colistinase. J. Antibiot. (Tokyo) 33(12), 1151-1555 (1980).
37. Souli M, Kontopidou FV, Koratzanis E et al. In vitro activity of tigecycline against multiple-drug resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals. Antimicrob. Agents Chemother. 50(9), 3166-3169 (2006).
38. Sentürk S. Evaluation of the anti-endotoxic effect of polymyxin-E (colistin) in dogs with naturally occurred endotoxic shock. J. Vet. Pharmacol. Ther. 28(1), 57-63 (2005).
39. Catchpole CR, Andrews JM, Brenwald N, Wise R. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J. Antimicrob. Chemother. 39(2), 255-260 (1997).
40. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents 5(1), 11-25 (2005).
41. Rastogi N, Potar MC, David HL. Antimycobacterial spectrum of colistin (polyntyxin E). Ann. Inst. Pasteur Microbiol. 137A(1), 45-53 (1986).
42. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin against 54731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance program (2001-2004). Clin. Microbiol. Infect. 12(4), 315-321 (2006).
43. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann. Pharmacother. 33(9), 960-970 (1999).
44. Li J, Coulthard K, Milne RW et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother. 52(6), 987-992 (2003).
45. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobic disc susceptibility tests. Approved standard M2-A2 S2. National Committee for Clinical Laboratory Standards, PA, USA (1981).
46. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J. Clin. Microbiol. 39(1), 183-190 (2001).
47. Committee Mot SA. Comité De I'Antibiogramme de la Societé Francaise de Microbiologie, report 2003. Int. J. Antimicrob. Agents 21(4), 364-391 (2003).
48. Andrews JM. BSAC standarudized disc susceptibility testing method. J. Antimicrob. Chemother. 48(Suppl. 1), 43-57 (2001).
49. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 16th International Supplement M-100-S15. CLSI, PA, USA (2005).
50. Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H. In vitro interaction of colistin and rifampin on multidrug resistant Pseudomonas aeruginosa. J. Chemother. 15(3), 235-238 (2003).
51. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampin on multidrug resistant Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 40(3), 117-120 (2001).
52. Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn. Microbiol. Infect. Dis. 44(3), 259-263 (2002).
53. Jimenez-Mejias ME, Pichardo-Guerrero C, Marques-Rivas FJ, Martin-Lozano D, Prados T, Pachon J. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parametrs of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 21(3), 212-214 (2002).
54. Coly-mycin M parenteral (package insert). Monarch Pharmaceuticals, TN, USA (2002).
55. Li J, Rayner CR, Nation RL et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob. Agents Chemother. 49(11), 4814-4815 (2005).
56. Reed MD, Stern RC, O'Riordan MA et al. The pharmacokinitics of colistin in patients with cystic fibrosis. J. Clin. Pharmacol. 41(6), 645-6541 (2001).
57. Leroy P, Decolin D, Nicolas S et al. Residue determination of two co-administered antibacterial agents-cephalexin and colistinin calf tissues using high-performance liquid chromatography and microbiological methods. J. Pharm. Biomed. Annal. 7(12), 1837-1846 (1989).
58. Li J, Milne RW, Nation RL et al. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J. Chromatogr. B. Biomed. Sci. Appl. 761(2), 167-175 (2001).
59. Li J, Milne RW, Nation RL et al. Simple method for assaying colistin methanesulfonate in plasma and urine using high performance liquid chromatography. Antimicrob. Agents Chemother. 46(10), 3304-3307 (2002).
60. Kunin CM, Bugg A. Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J. Infect. Dis. 124(4), 394-400 (1971).
61. Li J, Turnidge J, Milne R et al. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 45(3), 781-785 (2001).
62. Levin AS, Barone AA, Penço J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 28(5), 1008-1011 (1999).
63. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infections due to antimicrobial-resistant Pseudomonas aeruginosa. Clin. Infect. Dis. 37(11), 154-160 (2003).
64. Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit. Care 7(5), 78-83 (2003).
65. Ouderkirk, JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob. Agents Chemother. 47(8), 2659-2662 (2003).
66. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresisrant Gram-negative bacteria: the renaissance of an old antibiotic. Clin. Microbiol. Infect. 11(2), 115-121 (2005).
67. Kasiakou SK, Michalopoulos A, Soteriadcs E, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob. Agents Chemother. 49(8), 3136-3146 (2005).
68. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin. Infect. Dis. 36(9), 1111-1118 (2003).
69. Reina R, Estenssoro E, Sáenz G et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med. 31(8), 1058-1065 (2005).
70. Kwa ALH, Loh CS, Low GH, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin. Infect. Dis. 41(5), 754-757 (2005).
71. Katragkou A, Roilicles E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J. Clin. Microbiol. 43(9), 4916-4917 (2005).
72. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann. Intern. Med. 72(4), 857-868 (1970).
73. Brown JM, Dorman DC, Roy LP. Acute renal failure due to overdosage of colistin. Med. J. Aust. 2(20), 923-924 (1970).
74. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaides GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int. J. Antimicrob. Agents 26(6), 504-507 (2005).
75. Falagas ME, Rizos M, Bliziotis A, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BML Infect. Dis. 5(1), 1-8 (2005).
76. Bosso JA, Liptak CA, Seilheimer DK, Harrison GM. Toxicity of colistin in cystic fibrosis patients. DICP 25(11), 1168-1170 (1991).
77. Randall RE, Bridi GS, Setter JG, Brackett NC. Recovery from colistimethate nephroroxicity. Ann. Intern. Med. 73(3), 491-492 (1970).
78. Cunningham S, Prasad Collyer L, Carr S, Lynn IB, Wallis C. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch. Dis. Child. 84(5), 432-433 (2001).
79. Levin AS. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin. Microbiol. Infect. 8(3), 144-153 (2002).
80. Kiffer CRV, Sampaio, JLM, Sinto S et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 52(4), 317-322 (2005).
81. Meyers BR, Wilkinson P, Mendelson MH et al. Pharmacokinetics of ampicillin-sulbacam in healthy elderly and young volunteers. Antimicrob. Agents Chemother. 35(10), 2098-2101 (1991).
82. Valcke YJ, Rosseel MT, Pauwels RA, Bogaert MG, Van der Straeten ME. Penetration of ampicillin and sulbactam in the lower airways during respiratory infections. Antimicrob. Agents Chemotber. 34(6), 958-962 (1990).
83. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann. Pharmacother. 38(9), 1449-1459 (2004).
84. Wolf M, Joly-Guillou MR, Farinotti R, Carbon C. In vivo efficacies of combinations of β-lactams, β-lactamase inhibitors and rifampin again st Acinetobacter baumannii in a mouse pneumonia model. Antimicrob. Agents Chemother. 43(6), 1406-1411 (1999).
85. Corbella X, Ariza J, Ardanny C et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J. Antimicrob. Chemother. 42(6), 793-802 (1998).
86. Cisneros JM, Reyes MJ, Pachon J et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings and prognostic features. Clin. Infect. Dis. 22(6), 1026-1032 (1996).
87. Jellison TK, McKinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy 21(2), 142-148 (2001).
88. Wood GC, Hanes SD, Groce MA, Fabrian TC, Boncher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin. Infect. Dis. 34(11), 1425-1430 (2002).
89. Levin AS, Levy CE, Manrique AEI, Medeiros ES, Costa JF. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin-sulbactam. Int. J. Antimicrob. Agents. 21(1), 58-62 (2003).
90. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis. 41(Suppl. 5), 289-367 (2005).
91. Jones CH, Petersen PJ. Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic. Drugs Today 41(10), 637-659 (2005).
92. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother. 47(1), 400-404 (2003).
93. Betrieu C, Rodriguez-Avial I, Sanchez BA et al. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob. Agents Chemother. 46(3), 892-895 (2002).
94. Biedenbach DJ, Beach MI, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases. Diagn. Microbiol. Infect. Dis. 40(2), 173-177 (2001).
95. Cercenado E, Cercenado S, Gomez JA, Bouza E. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glucopeptides. J. Antimicrob. Chemother. 52(1), 138-139 (2003).
96. Deshpande LM, Gales AC, Jones RN. GAR-936 susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria. Intern. J. Antimicrob. Agents 18(1), 29-35 (2001).
97. Jacobus NY, McDermott LA, Ruthazer R, Snydman DR. In vitro activity of tigecycline against the Bacteroides fragilis group, Antimicrob. Agents Chemother. 48(3), 1034-1036 (2004).
98. Goldstein EJC, Citron DM, Merriam CV, Warren Y, Tyrrell K. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob. Agents Chemother. 44(10), 2747-2751 (2000).
99. Petersen PJ, Jacobs NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43(4), 738-744 (1999).
100. Meagher AK, Ambrose PC, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis. 41(Suppl. 5), 333-340 (2005).
101. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E, for the Tigecycline 300 and 305 cSSSI Study Groups. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase 3 comparison studies with vancomycin/ aztreonam. Clin. Infect. Dis. 41(Suppl. 5), 341-353 (2005).
102. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E, for the Tigecycline 301 and 306 Study Groups. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41(Suppl. 5), 354-366 (2005).
103. Lefort A, Lafaurei M, Massias L et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 47(1), 216-222 (2003).
104. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357(9263), 1179 (2001).
105. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Analysis of 2 double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124(5), 1789-1797 (2003).
106. Rupprecht TA, Pfister HW. Clinical experience with linezolid for the treatment of central nervous system infections. Curr. J. Neurol. 12(7), 536-542 (2005).
107. Fiscella RG, Lai WW, Buerk B et al. Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration. Ophthalmology 111(6), 1191-1195 (2004).
108. Attassi K, Hershberger E, Alam R, Zervos M. Thrombocytopenia associated with linezolid therapy. Clin. Infect. Dis. 34(5), 695-698 (2002).
109. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect. Dis. 4(8), 528-553 (2004).
110. Fagon JY, Patrick H, Haas DW et al. Treatment of Gram-positive nosocomial pneumonia. Prospsective randomized comparison of quinupristin/ dalfopristin versus vancomycin. Am. J. Respir. Crit. Care Med. 163(7), 753-762 (2000).
111. Linden PK, Moellering RI, Wood CA et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/ dalfopristin. Clin. Infect. Dis. 3301), 1816-1823 (2001).
112. Carver PL, Whang E, Vanden Bussche HL, Kauffman CA, Melani PN. Risk factors for arthralgias-myalgias associated with quinupristin/ dalfopristin therapy. Pharmacotherapy 23(2), 159-164 (2003).
113. Ellis MW, Lewis JS II. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr. Opin. Infect. Dis. 18(6), 496-501 (2005).
114. Cha R, Rybak MJ. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn. Microbiol. Infect. Dis. 47(3), 539-546 (2003).
115. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-syntethic penicillins for complicated skin and skin-structure infections. J. Antimicrob. Chemother. 55(2), 240-245 (2005).
116. Arbeit RD, Maki D, Tally FP et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38(12), 1674-1681 (2004).
117. Echevarria K, Dalta P, Cadena J, Lewis JS. Severe myopathy and possible hepatotoxicity related to daptomycin. J. Antimocrob. Chemother. 55(4), 599-800 (2005).
118. Mohan SS, McDermott BP, Cunha BA. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin. Heart Lung 34(1), 69-71 (2005).
119. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40(7), 1058-1060 (2005).
120. Lewis JS, Owens A, Cadena J et al. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob. Agents Chemother. 49(5), 1664-1665 (2005).
121. Pace JL, Yang G. Glycopeptides: update on an old successful antibiotic class. Biochem. Pharmacol. 71(7), 968-960 (2006).
122. Barrett JF. Oritavancin, Eli Lilly and Co. Curr. Opin. Investig. Drugs 2(8), 1039-1044 (2001).
123. Mercier RC, Hrebickova L. Oritavancin: a new avenue for resistant Gram-positive bacteria. Expert Rev. Anti-Infect. Ther. 3(3), 325-332 (2005).
124. Lin G, Credito K, Ednic LM, Appelbaum PC. Antistaphylococcal activity of dalbavancin,an experimental glycopeptide. Antimicrob. Agents Chemother. 49(2), 770-772 (2005).
125. Seltzer E, Dort MB, Goldstein BP, Perry M, Dowell JA, Henkel T. Once weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. The dalbavancin skin and soft-tissue infection study group. Clin. Infect. Dis. 37(10), 1298-1303 (2003).
126. Raad I, Darouiche R, Vasquez J et al. Efficacy and safely of weekly dalbavancin therapy for catheter-related bloodstream/infection caused by Gram-positive pathogens. Clin. Infect. Dis. 40(3), 374-380 (2005).
127. Bosso JA. The antimicrobial armamentarium: evaluating current and future treatment options. Pharmacotherapy 25(10 Pt 2), S55-S62 (2005).
128. Show JP, Seroogy J, Kaniga K, Higgins DL, Kit M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49(1), 195-201 (2005).
129. Stryjewski ME, O'Riordan WD, Lan WK et al, for the FAST Investigator groups. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections, due to Gram-positive bacteria. Clin. Infect. Dis. 40, 1601-1607 (2005).
130. Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in health subjects. J. Clin. Pharmacol. 44(7), 689-695 (2004).
131. Hancock RE. Cationic antimicrobial peptides: towards clinical applications. Exp. Opin. Invest. Drugs 9(8), 1723-1729 (2000).
132. Shinefield.H, Black S, Fattom A et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346(7), 496-496 (2002).
133. Hall AE, Domanski PJ, Patell PR et al. Characterization of a protective monoclonal antibody recognizing Staphylococcs aureus MSCRAMM protein clamping factor A. Infect. Immun. 71(12). 6864-6870 (2003).